ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1175

ABCG2 May Influence Risk Of Gout Through Extra-Renal Metabolic Pathways: Analysis Of The Effects Of The Q141K Variant On Serum Urate Responses To a Fructose Load

Nicola Dalbeth1, Meaghan House2, Gregory Gamble2, Bregina Pool1, Anne Horne2, Lauren Purvis2, Angela Stewart2, Marilyn E. Merriman3, Murray Cadzow4, Amanda Phipps-Green3 and Tony R. Merriman3, 1Medicine, University of Auckland, Auckland, New Zealand, 2Department of Medicine, University of Auckland, Auckland, New Zealand, 3Department of Biochemistry, University of Otago, Dunedin, New Zealand, 4University of Otago, Dunedin, New Zealand

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Gene Expression, Gout and uric acid, Kidney

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Metabolic and Crystal Arthropathies I

Session Type: Abstract Submissions (ACR)

Background/Purpose: Genetic variation in ABCG2 is a major risk factor for hyperuricemia and gout.  This gene encodes a high-capacity urate transporter expressed in the intestine, liver and renal tubule.  Intake of fructose-containing beverages is also associated with development of hyperuricaemia and gout.  A recent report has shown that variation in the other major genetic risk factor for gout, SLC2A9, influences serum urate (SU) and fractional excretion of uric acid (FEUA) responses to a fructose load. The aim of this study was to test the hypothesis that the ABCG2 gout risk allele 141K also promotes the hyperuricemic response to fructose loading.

Methods: Healthy volunteers (n=74) provided serum and urine samples immediately before and 30, 60, 120 and 180 minutes after ingesting a 64g fructose solution.  Data were analyzed based on the presence or absence of the ABCG2 141K gout risk allele using a mixed models approach to repeated measures. 

Results: The 141K risk allele was present in 23 participants (31%). Overall, SU concentrations during the fructose load were similar in those with and without the 141K allele (PSNP=0.15).  However, the presence of the 141K risk allele was associated with a smaller increase in SU following fructose intake (PSNP<0.0001) (Figure 1A). Those with the 141K allele also had a smaller increase in serum glucose following the fructose load (PSNP=0.002) (Figure 1B). Higher FEUA at baseline and throughout the fructose load was observed in those with the 141K risk allele (PSNP<0.0001).  However, the change in FEUA in response to fructose was not different in those with and without the 141K risk allele (PSNP=0.39).

Conclusion: In contrast to the predicted responses for a hyperuricemia/gout risk allele, the ABCG2 141K allele is associated with smaller increases in SU following a fructose load.  The FEUA data provide further evidence that the ABCG2 141K allele does not increase hyperuricemia/gout risk through direct effects on renal tubular uric acid transport.  Rather, the results suggest that ABCG2 variants may act through extra-renal metabolic pathways, which, in turn, influence SU levels and gout risk.

Figure 1: A. Change in SU. B. Change in serum glucose. Data are presented as mean (95% CI).  Dashed line represents 141K (risk) allele absent, solid line represents 141K (risk) allele present.


Disclosure:

N. Dalbeth,
None;

M. House,
None;

G. Gamble,
None;

B. Pool,
None;

A. Horne,
None;

L. Purvis,
None;

A. Stewart,
None;

M. E. Merriman,
None;

M. Cadzow,
None;

A. Phipps-Green,
None;

T. R. Merriman,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/abcg2-may-influence-risk-of-gout-through-extra-renal-metabolic-pathways-analysis-of-the-effects-of-the-q141k-variant-on-serum-urate-responses-to-a-fructose-load/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology